Navigation Links
ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
Date:10/1/2008

HALIFAX, Oct. 1 /PRNewswire/ - ImmunoVaccine Technologies' (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease vaccine models. The results of this research will be presented October 4th at the Ehrlich II conference in Germany. Collaborators from the University of Miami will also be reporting on the capabilities of IVT's depot formulations for delivery of DNA and SiRNA in vivo.

DepoVax(TM) provides a unique single-dose capability, and is based on a novel approach to the use of liposomes, which encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity.

The efficacy of a single dose of a DepoVax(TM) formulation was shown using a Human Papilloma Virus (HPV) associated cervical cancer model. In the therapeutic C3 tumor challenge model, DepoVax(TM) eliminated 100% of established cancerous tumors after a single dose. In contrast, tumors remained intact when treated with a placebo vaccine. The effect of the vaccine is linked to the activation of a potent and specific cellular immune response.

"We have developed depot vaccine formulations that can induce a more effective immune response than other vaccination strategies used in the clinic today," said Dr. Marc Mansour, vice president of R&D at IVT. "We look forward to testing our therapeutic cancer formulations in the clinic this coming year."

For the humoral response, a recombinant H5 antigen was used. IVT immunized models once with the DepoVax(TM) vaccine formulation, and once or twice with a control alum-based vaccine for avian influenza. At all time points tested, as early as 18 days and for at least 20 weeks, antibody titers induced by the depot vaccine were 10-15 times higher than a single dose of the control alum vaccine. The vaccine induced quick and strong specific immunity against the avian influenza antigen. In the longer term, the antibody responses generated were superior or equal to the two-dose alum vaccine.

"Typically, vaccines need booster shots to be effective, which is not an option in a pandemic situation," said Mansour. "Our depot vaccine formulation makes a single-dose pandemic flu vaccine a strong possibility."

IVT's strategy is multi-targeted; the company is exploring pandemic and seasonal influenza, as well as Hepatitis B. In addition, IVT is designing HLA-A2 peptide-based therapeutic depot vaccines for breast, ovarian and prostate cancers. By using tumor-specific peptides, IVT's depot vaccines induce a potent cellular response that destroys 100% of the tumors, indicating a promising immunotherapy for cancer.

About IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines. http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
2. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
3. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
6. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
7. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
8. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
9. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
10. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):